Karen N. Prange

Outset Medical is changing dialysis – one of the largest, most expensive, and stagnant areas of healthcare. Headquartered in San Jose, California, Outset operates across the United States and manufactures in North America. Our team is innovative, talented, and growing quickly. We are focused on creating change, driving widespread adoption of new technology, and delivering on the promise of an improved experience for patients and lower cost of care for healthcare providers. We are fueled by the opportunity to give people their lives back. When we succeed, patients will be able to fit dialysis into their life instead of fitting their life around dialysis. They will ultimately determine when, where, and how they dialyze.

At embecta (formerly part of BD) we are a global medical technology company singularly focused on improving the lives of people living with diabetes. For nearly 100 years, we’ve been developing and providing solutions to the diabetes community. We are the leaders in insulin delivery, with more than 30 million people in over 100 countries relying on our pen needle and syringe products. BD is the manufacturer of the advertised products. Privacy Policy: https://www.embecta.com/en-us/about/policies/privacy-policy-statement

Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines more than 140 years’ experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. Today, one out of three hearing aids is made by us and we are active in over 130 markets, employing 12,000 people worldwide. Our broad portfolio of leading hearing-related products and services generates annual revenues of € 2,351 million. WS Audiology is privately owned by the Tøpholm and Westermann families, as well as funds under the management of EQT. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone’s life.

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which contribute to improved outcomes. Cantel is now a part of STERIS.

Outset Medical is changing dialysis – one of the largest, most expensive, and stagnant areas of healthcare. Headquartered in San Jose, California, Outset operates across the United States and manufactures in North America. Our team is innovative, talented, and growing quickly. We are focused on creating change, driving widespread adoption of new technology, and delivering on the promise of an improved experience for patients and lower cost of care for healthcare providers. We are fueled by the opportunity to give people their lives back. When we succeed, patients will be able to fit dialysis into their life instead of fitting their life around dialysis. They will ultimately determine when, where, and how they dialyze.

At embecta (formerly part of BD) we are a global medical technology company singularly focused on improving the lives of people living with diabetes. For nearly 100 years, we’ve been developing and providing solutions to the diabetes community. We are the leaders in insulin delivery, with more than 30 million people in over 100 countries relying on our pen needle and syringe products. BD is the manufacturer of the advertised products. Privacy Policy: https://www.embecta.com/en-us/about/policies/privacy-policy-statement

Joe DiMaggio Childrens Hospital is one of the regions leading pediatric hospitals, offering a comprehensive scope of healthcare services and programs in a child-friendly atmosphere. Established in 1992, it combines advanced technology and the expertise of the largest, most diverse group of board-certified pediatric specialists in the region.

At ViewRay, our vision is clear: conquer cancer by re-envisioning radiation therapy., giving doctors new and better ways to treat their patients. ViewRay®, Inc. (NASDAQ:VRAY) shifts the paradigm in cancer treatment with the MRIdian® MRI-guided adaptive radiotherapy system. We’re changing radiation therapy for the better with accurate, precise and personalized cancer treatment that no other system delivers, addressing the key limitations of existing external-beam radiation therapy technologies. Real-time imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian shapes the dose to fit the day. It’s the only MR solution that enables fully integrated adaptive treatment with complete, on-table re-optimization of the daily treatment plan. It knows when to strike – and when to stop. MRIdian is the only RT solution with automated beam gating for precise and accurate dosing. When the tumor moves, the beam stops. The result? Better outcomes for patients. After seven years of clinical use, MRIdian has treated more than 12,500 patients worldwide. We’re an innovative, entrepreneurial company with big ambitions, unlimited potential and a passion for a culture that is diverse and committed to our physicians and their patients. If you’re ready to change the way the world views cancer, come join our team.

A global private markets firm. 30+ years of unlocking returns and growth for investors beyond public markets.